Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (40)	3/20/1998 7:18:00 PM
From: BDR	Read Replies (1) \| Respond to of 138

In February, 1997, Inactivin was DHEA. In February, 1998, Inactivin is now PPB2. What's the difference between a formulation and an analog? Sounds like we are talking about the same thing. From the recent press release (http://biz.yahoo.com/prnews/980209/ca_hollis__1.html) The company recently developed PPB2, trade named (INACTIVIN) a new analog of the company's lead drug candidate, that has a unique mechanism of action for antiretroviral... The following is from the S4/A filed 2/97. INACTIVIN: ANTI-VIRAL FORMULATION OF DEHYDROEPIANDROSTERONE (DHEA) Background. In 1987, Colthurst Limited ("Colthurst") originally licensed DHEA to Elan Pharmaceutical Ltd. ("Elan"). Elan obtained a clinical Investigational New Drug ("IND") with the FDA and conducted a Phase I escalation study. The results of this study showed no toxicity and found that patients tolerated the drug with no side effects. However, Elan chose to use its own formulation of DHEA instead of the pharmaceutical preparation advanced by Dr. Prendergast. Subsequently, this Phase I study did not demonstrate clinical efficacy. In 1992, Colthurst and Elan ended their five-year agreement. Colthurst continued work on refining DHEA's pharmaceutical formulation and relicensed the drug in 1994 to Hollis-Eden. Dr. Prendergast discovered that his formulation of DHEA (INACTIVIN) was critical to the drug's ability to penetrate into the cytoplasm of the cell to show its antiviral effectiveness. treatment in HIV/AIDS and other infectious diseases.

To: BDR who wrote (40)	3/30/1998 2:54:00 PM
From: Jumper	Respond to of 138

OT- Dale, I see the situation is well in hand here with the arrival of genuine HEPH shareholders. IIRG has been a source of great amusement in the past and I invite all the shorts to drop in on one of these road shows. I suggest grabbing two complementary cocktails at a time as this double fisting approach helps subdue the urge for laughter. As a fill in for any down time such as a slide of revenue growth projections during the low ball toutorama I personally like to compare and contrast hair implants. All the best.